» Articles » PMID: 11761433

Endocrine Inactive and Gonadotroph Adenomas: Diagnosis and Management

Overview
Journal J Neurooncol
Publisher Springer
Date 2002 Jan 5
PMID 11761433
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Endocrine inactive pituitary adenomas represent about one quarter of all pituitary tumors. By immunocytochemistry, most of these tumors are positive for intact gonadotropins and/or their subunits. Clinical presentation is usually secondary to mass effect symptoms, such as visual disturbances, headache, and hypopituitarism. Differential diagnosis is usually accomplished by neuroradiologic studies, even though in selected cases positron emission tomography and/or single photon emission tomography may aid to distinguish pituitary adenomas from other endocrine inactive lesions, such as meningiomas and craniopharyngiomas. Surgical management is usually considered the first choice treatment for patients with endocrine inactive pituitary adenomas because it is very effective in ameliorating symptoms of chiasmal compression and headache. Radical removal of the tumor, however, is difficult to obtain because of the frequent invasiveness into the cavernous sinus. Radiation therapy diminishes the likelihood of tumor recurrence, especially in patients with demonstrable tumor remnants after surgery. Medical therapy with dopaminergic drugs, somatostatin analogs, or gonadotropin-releasing hormone agonists or antagonists causes mild reduction of tumor size in few patients and, therefore, seems to be of limited value in the therapeutic management of patients with endocrine inactive pituitary adenomas.

Citing Articles

Medical and Surgical Approaches for a Non-functioning Pituitary Adenoma During Pregnancy.

Taieb A, Ben Haj Slama N, Mraihi E, Nouri H, Bannour I Cureus. 2024; 16(3):e55512.

PMID: 38571819 PMC: 10990650. DOI: 10.7759/cureus.55512.


Non-functioning pituitary adenomas and pregnancy: one-center experience and review of the literature.

Rosmino J, Tkatch J, Di Paolo M, Berner S, Lescano S, Guitelman M Arch Endocrinol Metab. 2021; 64(5):614-622.

PMID: 34033303 PMC: 10118964. DOI: 10.20945/2359-3997000000232.


Somatostatin Analogs in Clinical Practice: a Review.

Gomes-Porras M, Cardenas-Salas J, Alvarez-Escola C Int J Mol Sci. 2020; 21(5).

PMID: 32121432 PMC: 7084228. DOI: 10.3390/ijms21051682.


Functional Gonadotroph Adenomas: Case Series and Report of Literature.

Cote D, Smith T, Sandler C, Gupta T, Bale T, Bi W Neurosurgery. 2015; 79(6):823-831.

PMID: 26692108 PMC: 4912468. DOI: 10.1227/NEU.0000000000001188.


Prediction of Long-term Post-operative Testosterone Replacement Requirement Based on the Pre-operative Tumor Volume and Testosterone Level in Pituitary Macroadenoma.

Lee C, Chen C, Lee S, Wei K, Pai P, Toh C Sci Rep. 2015; 5:16194.

PMID: 26537232 PMC: 5155724. DOI: 10.1038/srep16194.


References
1.
Faggiano M, Criscuolo T, Perrone L, Quarto C, Sinisi A . Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma. Acta Endocrinol (Copenh). 1983; 102(2):167-72. DOI: 10.1530/acta.0.1020167. View

2.
Sassolas G, Trouillas J, Treluyer C, Perrin G . Management of nonfunctioning pituitary adenomas. Acta Endocrinol (Copenh). 1993; 129 Suppl 1:21-6. View

3.
Klibanski A, Jameson J, Biller B, Crowley Jr W, Zervas N, Rivier J . Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors. J Clin Endocrinol Metab. 1989; 68(1):81-6. DOI: 10.1210/jcem-68-1-81. View

4.
de Herder W, Lamberts S . Imaging of pituitary tumours. Baillieres Clin Endocrinol Metab. 1995; 9(2):367-89. DOI: 10.1016/s0950-351x(95)80402-1. View

5.
Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F . In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090). J Clin Endocrinol Metab. 1991; 73(4):850-6. DOI: 10.1210/jcem-73-4-850. View